A Phase 2/3 interventional study of rMenB+OMV NZ with routine vaccinations and rMenB+OMV NZ with routine vaccinations in Meningococcal Disease and Meningococcal Meningitis, sponsored by Novartis Vaccines. Completed at 72 sites in 6 countries. Open to participants aged 12 Months to 24 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-08-14.
Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal — 1 open to participants now, 2 under way, none of them phase 3. 4CMenB vaccine · Meningitis, Meningococcal.
Among the 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal, this one has the largest enrollment, is one of 2 that started in 2009, is the only one in phase 2/3, and was the 3rd registered.
125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.
Browse Meningitis, Meningococcal studies →1 of the 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal is open now, in 1 country. Recruiting first, the newest first:
University Ghent · Sites in Belgium
Ages 18–50 · Healthy volunteers
By country, each count listing its studies:
4CMenB vaccine: first FDA approval 2014 (Trumenba). What it is approved for, and how studies give it, is on its page →
Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 12 Months to 24 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 4 · Phase 4 4
First in 2006; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,588 is above the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.
Median enrollment 250 across the 11 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 6 most frequent:
This study is registered under Novartis Vaccines, one of the names counted as Novartis. Under that name alone:
Novartis Vaccines is the lead sponsor of 165 studies on the registry; none are open to participants now.
32 studies in Meningitis, Meningococcal by Novartis: none open now, none under way, none of them phase 3. Of 32 finished, 28 (88%) have results posted.
Among the 32 studies in Meningitis, Meningococcal by Novartis, this one is the 6th largest by enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2009, is one of 2 in phase 2/3, and was the 13th registered.
Novartis’s Meningitis, Meningococcal studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 32 in Meningitis, Meningococcal:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This extension study V72P12E1 will investigate the safety, tolerability and immunogenicity of a fourth (booster) dose of rMenB+OMV NZ at 12, 18 and 24 months of age in subjects previously primed with rMenB+OMV NZ according to two different three-dose immunization schedules in infancy (2, 4 and 6 or 2, 3 and 4 months of age in the parent study V72P12). The study will also explore the bactericidal antibody persistence at 12, 18 and 24 months of age, following the two different immunization schedules, in order to identify the optimal timing for boosting. Two catch-up rMenB+OMV NZ doses will be given to unprimed, naïve toddlers at 12 (subjects enrolled in the control group of V72P12), 18 and 24 months of age (two new cohort of subjects enrolled). These subjects will generate data for assessing the safety and immunogenicity of a two-dose catch-up regimen at these ages, but will also serve as controls for a descriptive comparison of antibody persistence and booster responses for the other groups.
125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.
This study's enrollment of 1,588 is above the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.
Browse Meningitis, Meningococcal studies →Novartis Vaccines is the lead sponsor of 165 studies on the registry; none are open to participants now.
First submitted before Novartis Vaccines left Novartis.
Compared within Meningitis, Meningococcal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Meningococcal Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Follow-on participants of V72P12:
Healthy toddlers who completed Study V72P12, aged:
Naive subjects newly enrolled:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.
Biological: rMenB+OMV NZ with routine vaccinations
Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.
Biological: rMenB+OMV NZ with routine vaccinations
Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.
Biological: rMenB+OMV NZ with routine vaccinations
Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.
Biological: rMenB+OMV NZ
Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3,5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 18 months of age.
Biological: rMenB+OMV NZ
Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 24 months of age.
Biological: rMenB+OMV NZ
Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ at 12 months of age.
Biological: rMenB+OMV NZ with routine vaccinations
Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.
Biological: rMenB+OMV NZ with routine vaccinations
Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.
Biological: rMenB+OMV NZ with routine vaccinations
Previously received two catch-up doses of rMenB+OMV NZ vaccine at 12 and14 months of age.
Biological: two doses of rMenB+OMV NZ
Previously received two catch-up doses of rMenB+OMV NZ vaccine at 18 and 20 months of age.
Biological: two doses of rMenB+OMV NZ
Previously received two catch-up doses of rMenB+OMV NZ vaccine at 24 and 26 months of age.
Biological: two doses of rMenB+OMV NZ
rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 12 months of age
rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 18 months of age
Drug page: 4CMenB vaccine
rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 12 months of age
Drug page: 4CMenB vaccine
rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 18 months of age
rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 12 months of age
rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 18 months of age
two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age.
rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 24 months of age
two catch-up doses of rMenB+OMV NZ at 18 and 20 months of age
Drug page: 4CMenB vaccine
rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 24 months of age
two catch-up doses of rMenB+OMV NZ at 24 and 26 months of age
rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 12 (Group 3a), 18 (Group 3b) or 24 (Group 3c) months of age
Percentages of Subjects With Serum Bactericidal Antibody Titers ≥1:5 After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in Subjects Who Previously Received 3 Doses of rMenB+OMV NZ and Routine Vaccines at 2, 4 and 6 Months of Age.
Immunogenicity was assessed in terms of percentage of subjects with serum bactericidal antibody (SBA) titers ≥1:5 (98.3% CI) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99, one month after the fourth (booster) dose of meningococcal B vaccine at 12 or 18 or24 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ and routine vaccines at 2, 4 and 6 months of age.
Time frame: 1 month after booster
Percentages of Subjects With SBA Titers ≥1:5 After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in Subjects Who Previously Received 3 Doses of rMenB+OMV NZ at 2, 4 and 6 Months of Age and Routine Vaccines at 3, 5 and 7 Months of Age.
Immunogenicity was assessed in terms of Percentages of Subjects With SBA Titers ≥1:5 (98.3% CI), After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in subjects who previously received 3 doses of rMenB+OMV NZ at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age.
Time frame: 1 month after booster
Percentages of Subjects With Serum Bactericidal Antibody Titers ≥1:5 After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in Subjects Who Previously Received 3 Doses of rMenB+OMV NZ and Routine Vaccines at 2, 3 and 4 Months of Age.
Immunogenicity was assessed in terms of percentage of subjects with serum bactericidal antibody (SBA) titers ≥1:5 (98.3% CI) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99, one month after the fourth (booster) dose of meningococcal B vaccine at 12 or 18 or24 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ and routine vaccines at 2, 3 and 4 months of age.
Time frame: 1 month after booster
Geometric Mean Titers (GMTs) in Subjects One Month After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in Subjects at 12 18 or 24 Months of Age Who Previously Received 3 Doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 Months of Age.
The serum antibody titers one month after the fourth (booster) dose of meningococcal B vaccine at 12 or 18 or24 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 months of age, are reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.
Time frame: 1 month after booster
GMTs in Subjects One Month After the Fourth (Booster) Dose of Meningococcal B Vaccine at 12 Months of Age Previously Vaccinated With 3 Doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 Months of Age and Single Dose of rMenB+OMV NZ Given at Same Age
Characterization of immunological memory by serum antibody titers (98.3% CI) one month after the fourth (booster) dose of meningococcal B vaccine at 12 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 months of age and single dose of rMenB+OMV NZ given at same ages, are reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.
Time frame: 1 month after booster
GMTs in Subjects One Month After the Fourth (Booster) Dose of Meningococcal B Vaccine at 18 and 24months of Age, Previously Vaccinated With 3 Doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 Months of Age and Single Dose of rMenB+OMV NZ Given at Same Age
Characterization of immunological memory by serum antibody titers one month after the fourth (booster) dose of meningococcal B vaccine at 18 and 24months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 months of age and single dose of rMenB+OMV NZ given at same ages, are reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.
Time frame: 1 month after booster
Two-dose Catch-up Regimen of rMenB+OMV NZ in Unprimed Toddlers Aged 12, 18 or 24 Months
Immunogenicity evaluation of a two-dose catch-up regimen of rMenB+OMV NZ in unprimed toddlers aged 12, 18 or 24 months as measured by serum antibody titers one month after the second vaccination f meningococcal B vaccine at 18 and 24months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.
Time frame: 1 month after second vaccination
Geometric Mean Concentrations Against Vaccine Antigen 287- 953 One Month After Fourth Booster Dose to Previously Primed Toddlers at 12, 18 or 24 Months of Age.
Immunogenicity evaluation against vaccine antigen 287-953 one month after fourth booster dose to previously primed toddlers at 12, 18 or 24 months measured by ELISA.
Time frame: 1 month after booster vaccination
Geometric Mean Concentrations Against Vaccine Antigen 287- 953 One Month After Booster Given After a Two-dose Catch-up Regimen in Toddlers Starting at 12, 18 or 24 Months of Age.
Immunogenicity evaluation against vaccine antigen 287-953 one month after booster given after a two-dose catch-up regimen in toddlers starting at 12, 18 or 24 months of age.one month after fourth booster dose to previously primed toddlers at 12, 18 or 24 months of age measured by ELISA
Time frame: 1 month after booster vaccination
Number of Children Reporting Solicited Local and Systemic Adverse Events After Receiving a Fourth Booster Dose of rMenB+OMV NZ Vaccine at 12, 18 or 24 Months of Age.
The safety and tolerability of the 4th booster dose rMenB+OMV NZ vaccine in children (12, 18 or 24 months age) is reported as number of subjects with solicited local and systemic adverse events.
Time frame: From day 1 to day 7 after vaccination
Number of Children Reporting Solicited Local and Systemic Adverse Events After Receiving a Two-dose Catch-up Regimen of rMenB+OMV NZ Vaccine at 12, 18 or 24 Months of Age.
The safety and tolerability of the two-dose catch-up regimen of rMenB+OMV NZ vaccine in children (12, 18 or 24 months age) is reported as number of subjects with solicited local and systemic adverse events.
Time frame: day 1 to day 7 after vaccination
Subjects were enrolled from 6 centres in Belgium, 4 in Czech, 24 in Germany, 5 in Italy, 16 in Spain and 4 in UK who had previously participated in and completed the study V72P12.
| Milestone | B+R246_12 | B+R246_18 | B+R246_24 | B246_12 | B246_18 | B246_24 | B+R234_12 | B+R234_18 | B+R234_24 | B12 14 | B18 20 | B24 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 188 | 157 | 152 | 174 | 164 | 143 | 106 | 78 | 73 | 246 | 51 | 56 |
| Completed | 183 | 150 | 143 | 170 | 150 | 123 | 102 | 73 | 63 | 236 | 50 | 52 |
| Not completed | 5 | 7 | 9 | 4 | 14 | 20 | 4 | 5 | 10 | 10 | 1 | 4 |
| Withdrew: Inappropriate enrollment | 0 | 1 | 0 | 1 | 2 | 1 | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 2 | 6 | 2 | 5 | 8 | 2 | 2 | 3 | 4 | 0 | 4 |
| Withdrew: Lost to follow-up | 0 | 4 | 2 | 0 | 5 | 7 | 0 | 1 | 5 | 1 | 1 | 0 |
| Withdrew: Death | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 2 | 0 | 0 | 1 | 2 | 3 | 0 | 1 | 1 | 4 | 0 | 0 |
| Withdrew: Unable to classify | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Administrative reason | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
Immunogenicity was assessed in terms of percentage of subjects with serum bactericidal antibody (SBA) titers ≥1:5 (98.3% CI) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99, one month after the fourth (booster) dose of meningococcal B vaccine at 12 or 18 or24 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ and routine vaccines at 2, 4 and 6 months of age.
| percentage of subjects | B+R246_12 | B+R246_18 | B+R246_24 |
|---|---|---|---|
| hSBA≥ 1: 5 (H44/76 strain)(N = 158,116,101) | 97 (93 to 99) | 100 (96 to 100) | 100 (95 to 100) |
| hSBA≥ 1: 5 (5/99 strain)(N= 156,118,100) | 100 (97 to 100) | 100 (96 to 100) | 100 (95 to 100) |
| hSBA≥ 1: 5 (NZ 98/254 strain)(N= 159,118,103) | 95 (89 to 98) | 77 (67 to 86) | 84 (74 to 92) |
| hSBA≥ 1: 5 (M10713 strain) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Immunogenicity was assessed in terms of Percentages of Subjects With SBA Titers ≥1:5 (98.3% CI), After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in subjects who previously received 3 doses of rMenB+OMV NZ at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age.
| percentage of subjects | B246_12 | B246_18 | B246_24 |
|---|---|---|---|
| hSBA≥ 1: 5 (H44/76 strain)(N= 138,111,93) | 100 (97 to 100) | 99 (94 to 100) | 100 (95 to 100) |
| hSBA≥ 1: 5 (5/99 strain)(N= 142,110,92) | 100 (97 to 100) | 100 (96 to 100) | 100 (95 to 100) |
| hSBA≥ 1: 5 (NZ 98/254 strain)(N= 142,111,95) | 96 (90 to 99) | 86 (76 to 93) | 89 (80 to 96) |
| hSBA≥ 1: 5 (M10713 strain) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Immunogenicity was assessed in terms of percentage of subjects with serum bactericidal antibody (SBA) titers ≥1:5 (98.3% CI) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99, one month after the fourth (booster) dose of meningococcal B vaccine at 12 or 18 or24 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ and routine vaccines at 2, 3 and 4 months of age.
| percentage of subjects | B+R234_12 | B+R234_18 | B+R234_24 |
|---|---|---|---|
| hSBA≥ 1: 5 (H44/76 strain)(N= 83,56,48 ) | 100 (94 to 100) | 98 (88 to 100) | 100 (91 to 100) |
| hSBA≥ 1: 5 (5/99 strain)(N= 84,56,46) | 100 (94 to 100) | 100 (92 to 100) | 100 (90 to 100) |
| hSBA≥ 1: 5 (NZ 98/254 strain)(N= 83,56,48) | 97 (89 to 100) | 80 (65 to 91) | 96 (83 to 100) |
| hSBA≥ 1: 5 (M10713 strain)(N= 67,50,41) | 76 (62 to 87) | 74 (57 to 87) | 95 (81 to 100) |
The serum antibody titers one month after the fourth (booster) dose of meningococcal B vaccine at 12 or 18 or24 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 months of age, are reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.
| Titers | B+R246_12 | B+R246_18 | B+R246_24 | B246_12 | B246_18 | B246_24 | B+R234_12 | B+R234_18 | B+R234_24 |
|---|---|---|---|---|---|---|---|---|---|
| hSBA≥ 1: 5 (H44/76 strain) | 125 (106 to 148) | 123 (101 to 149) | 108 (88 to 133) | 178 (149 to 213) | 164 (135 to 200) | 152 (122 to 188) | 135 (108 to 170) | 92 (70 to 121) | 128 (95 to 172) |
| hSBA≥ 1: 5 (5/99 strain) | 1276 (1092 to 1491) | 2183 (1824 to 2611) | 1820 (1497 to 2212) | 1713 (1454 to 2020) | 2058 (1710 to 2476) | 2739 (2233 to 3361) | 1558 (1262 to 1923) | 1486 (1148 to 1924) | 2081 (1564 to 2771) |
| hSBA≥ 1: 5 (NZ 98/254 strain) | 36 (29 to 44) | 15 (12 to 19) | 17 (14 to 22) | 34 (27 to 42) | 17 (14 to 22) | 19 (15 to 25) | 47 (36 to 62) | 17 (12 to 24) | 33 (23 to 47) |
| hSBA≥ 1: 5 (M10713 strain) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 12 (8.52 to 17) | 15 (10 to 23) | 26 (17 to 41) |
Characterization of immunological memory by serum antibody titers (98.3% CI) one month after the fourth (booster) dose of meningococcal B vaccine at 12 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 months of age and single dose of rMenB+OMV NZ given at same ages, are reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.
| Titers | B+R246_12 | B246_12 | B+R234_12 | B12 14 |
|---|---|---|---|---|
| hSBA≥ 1: 5 (H44/76 strain)(N= 158,138,83,217) | 125 (102 to 154) | 179 (144 to 223) | 137 (104 to 181) | 18 (15 to 21) |
| hSBA≥ 1: 5 (5/99 strain)(N= 156,142,84,216) | 1301 (1076 to 1573) | 1763 (1441 to 2157) | 1607 (1243 to 2077) | 49 (42 to 58) |
| hSBA≥ 1: 5 (NZ 98/254 strain)(N= 159,142,86,220) | 37 (29 to 46) | 35 (27 to 44) | 48 (36 to 65) | 3.71 (3.06 to 4.5) |
Characterization of immunological memory by serum antibody titers one month after the fourth (booster) dose of meningococcal B vaccine at 18 and 24months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 months of age and single dose of rMenB+OMV NZ given at same ages, are reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.
| Titers | B+R246_18 | B+R246_24 | B246_18 | B246_24 | B+R234_18 | B+R234_24 | B18 20 | B24 26 |
|---|---|---|---|---|---|---|---|---|
| hSBA≥ 1: 5 (H44/76 strain) | 126 (104 to 154) | 110 (89 to 136) | 162 (132 to 198) | 155 (124 to 193) | 93 (70 to 123) | 132 (97 to 180) | 18 (13 to 25) | 14 (10 to 19) |
| hSBA≥ 1: 5 (5/99 strain) | 2195 (1790 to 2691) | 1811 (1449 to 2262) | 2034 (1648 to 2511) | 2735 (2166 to 3455) | 1483 (1107 to 1986) | 2087 (1508 to 2889) | 41 (30 to 56) | 30 (22 to 41) |
| hSBA≥ 1: 5 (NZ 98/254 strain) | 16 (12 to 20) | 18 (14 to 23) | 17 (14 to 22) | 20 (15 to 26) | 17 (12 to 25) | 34 (23 to 49) | 2.76 (1.87 to 4.08) | 2.1 (1.44 to 3.07) |
Immunogenicity evaluation of a two-dose catch-up regimen of rMenB+OMV NZ in unprimed toddlers aged 12, 18 or 24 months as measured by serum antibody titers one month after the second vaccination f meningococcal B vaccine at 18 and 24months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.
| Titers | B12 14 | B18 20 | B24 26 |
|---|---|---|---|
| hSBA≥ 1: 5 (H44/76 strain)(N= 156,42,45) | 188 (164 to 216) | 171 (130 to 224) | 177 (136 to 231) |
| hSBA≥ 1: 5 (5/99 strain)(N= 177, 40,46) | 635 (548 to 735) | 491 (359 to 672) | 559 (417 to 749) |
| hSBA≥ 1: 5 (NZ 98/254 strain)(N = 179,44,45) | 40 (35 to 47) | 23 (17 to 30) | 24 (18 to 32) |
| hSBA≥ 1: 5 (M10713 strain)(N= 0,34,37) | NA (NA to NA) | 14 (8.02 to 23) | 18 (11 to 29) |
Immunogenicity evaluation against vaccine antigen 287-953 one month after fourth booster dose to previously primed toddlers at 12, 18 or 24 months measured by ELISA.
| IU/mL | B+R246_12 | B+R246_18 | B+R246_24 | B246_12 | B246_18 | B246_24 | B+R234_12 | B+R234_18 | B+R234_24 |
|---|---|---|---|---|---|---|---|---|---|
| Geometric Mean Concentrations Against Vaccine Antigen 287- 953 One Month After Fourth Booster Dose to Previously Primed Toddlers at 12, 18 or 24 Months of Age. | 5334 (4670 to 6093) | 6395 (5474 to 7470) | 6864 (5826 to 8087) | 6605 (5733 to 7609) | 6418 (5477 to 7520) | 8120 (6833 to 9649) | 6125 (5110 to 7342) | 5952 (4771 to 7426) | 6774 (5305 to 8649) |
Immunogenicity evaluation against vaccine antigen 287-953 one month after booster given after a two-dose catch-up regimen in toddlers starting at 12, 18 or 24 months of age.one month after fourth booster dose to previously primed toddlers at 12, 18 or 24 months of age measured by ELISA
| IU/mL | B12 14 | B18 20 | B24 26 |
|---|---|---|---|
| Geometric Mean Concentrations Against Vaccine Antigen 287- 953 One Month After Booster Given After a Two-dose Catch-up Regimen in Toddlers Starting at 12, 18 or 24 Months of Age. | 122 (101 to 147) | 121 (84 to 176) | 100 (69 to 144) |
The safety and tolerability of the 4th booster dose rMenB+OMV NZ vaccine in children (12, 18 or 24 months age) is reported as number of subjects with solicited local and systemic adverse events.
| participants | B246_12 | B246_18 | B246_24 |
|---|---|---|---|
| Any | 156 | 135 | 116 |
| Any Local | 137 | 119 | 113 |
| Injection site Tenderness | 104 | 104 | 105 |
| Injection site Erythema | 117 | 94 | 94 |
| Injection site Induration | 93 | 62 | 73 |
| Injection site Swelling | 57 | 52 | 50 |
| Any Systemic | 134 | 118 | 101 |
| ChangeEat.Habits | 66 | 59 | 51 |
| Sleepiness | 63 | 56 | 52 |
| Vomiting | 8 | 9 | 8 |
| Diarrhea | 37 | 23 | 27 |
| Irritbility | 104 | 91 | 83 |
| Unusual Crying | 52 | 51 | 40 |
| Rash | 7 | 3 | 7 |
| Fever ( >= 38C ) | 52 | 55 | 28 |
| Any Ohter | 59 | 59 | 40 |
| Body Temp. <38 C | 118 | 98 | 98 |
| Medical Attend. Fever | 5 | 5 | 2 |
| Antipyretic prophylactic | 32 | 28 | 25 |
| Antipyretic therapeutic | 37 | 39 | 21 |
The safety and tolerability of the two-dose catch-up regimen of rMenB+OMV NZ vaccine in children (12, 18 or 24 months age) is reported as number of subjects with solicited local and systemic adverse events.
| participants | B12 14 | B18 20 | B24 26 |
|---|---|---|---|
| Injection site Tenderness (vaccination 1) | 151 | 35 | 47 |
| Injection site Tenderness (vaccination 2) | 143 | 32 | 42 |
| Injection site Erythema (vaccination 1) | 151 | 32 | 39 |
| Injection site Erythema (vaccination 2) | 148 | 33 | 31 |
| Injection site Induration (vaccination 1) | 112 | 20 | 27 |
| Injection site Induration (vaccination 2) | 101 | 24 | 22 |
| Injection site Swelling (vaccination 1) | 81 | 15 | 19 |
| Injection site Swelling (vaccination 2) | 72 | 18 | 19 |
| Change in Eating habits (vaccination 1) | 95 | 13 | 25 |
| Change in Eating habits (vaccination 2) | 83 | 19 | 21 |
| Sleepiness (vaccination 1) | 106 | 21 | 18 |
| Sleepiness (vaccination 2) | 78 | 16 | 18 |
| Vomiting (vaccination 1) | 19 | 5 | 6 |
| Vomiting (vaccination 2) | 18 | 1 | 4 |
| Diarrhea (vaccination 1) | 43 | 13 | 20 |
| Diarrhea (vaccination 2) | 35 | 5 | 7 |
| Irritability (vaccination 1) | 156 | 23 | 28 |
| Irritability (vaccination 2) | 126 | 27 | 23 |
| Unusual Crying (vaccination 1) | 81 | 13 | 15 |
| Unusual Crying (vaccination 2) | 67 | 14 | 15 |
| Rash (vaccination 1) | 13 | 5 | 2 |
| Rash (vaccination 2) | 10 | 4 | 0 |
| Fever ( >= 38C ) (vaccination 1) | 83 | 14 | 15 |
| Fever ( >= 38C ) (vaccination 2) | 74 | 15 | 13 |
| Body Temp.<38 C (vaccination 1) | 156 | 37 | 39 |
| Body Temp.<38 C (vaccination 2) | 163 | 36 | 39 |
| Medical Attend. Fever (vaccination 1) | 9 | 2 | 1 |
| Medical Attend. Fever (vaccination 2) | 5 | 1 | 0 |
| Antipyretic prophylactic (vaccination 1) | 49 | 8 | 8 |
| Antipyretic prophylactic (vaccination 2) | 45 | 9 | 11 |
| Antipyretic therapeutic (vaccination 1) | 66 | 9 | 11 |
| Antipyretic therapeutic (vaccination 2) | 54 | 11 | 7 |
Collected over From day 1 to day 7 after vaccination. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| B+R246_12 | — | 5/185 (2.7%) | 180/185 (97.3%) |
| B+R246_18 | — | 3/152 (2%) | 147/152 (96.7%) |
| B+R246_24 | — | 6/144 (4.2%) | 140/144 (97.2%) |
| B246_12 | — | 6/170 (3.5%) | 163/170 (95.9%) |
| B246_18 | — | 7/153 (4.6%) | 139/153 (90.8%) |
| B246_24 | — | 1/126 (0.8%) | 116/126 (92.1%) |
| B+R234_12 | — | 5/104 (4.8%) | 102/104 (98.1%) |
| B+R234_18 | — | 5/74 (6.8%) | 73/74 (98.6%) |
| B+R234_24 | — | 3/66 (4.5%) | 62/66 (93.9%) |
| B12 14 | — | 16/239 (6.7%) | 230/239 (96.2%) |
| B18 20 | — | 0/51 (0%) | 50/51 (98%) |
| B24 26 | — | 1/55 (1.8%) | 54/55 (98.2%) |
| Event | B+R246_12 | B+R246_18 | B+R246_24 | B246_12 | B246_18 | B246_24 | B+R234_12 | B+R234_18 | B+R234_24 | B12 14 | B18 20 | B24 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GastroenteritisInfections and infestations | 0/185 | 1/152 | 0/144 | 0/170 | 2/153 | 0/126 | 0/104 | 2/74 | 0/66 | 2/239 | 0/51 | 0/55 |
| ConcussionInjury, poisoning and procedural complications | 0/185 | 0/152 | 0/144 | 1/170 | 1/153 | 0/126 | 0/104 | 0/74 | 0/66 | 1/239 | 0/51 | 1/55 |
| Head injuryInjury, poisoning and procedural complications | 0/185 | 0/152 | 0/144 | 0/170 | 0/153 | 0/126 | 0/104 | 0/74 | 1/66 | 1/239 | 0/51 | 0/55 |
| Febrile convulsionNervous system disorders | 0/185 | 0/152 | 2/144 | 0/170 | 0/153 | 0/126 | 1/104 | 0/74 | 1/66 | 3/239 | 0/51 | 0/55 |
| BronchiolitisInfections and infestations | 0/185 | 0/152 | 0/144 | 0/170 | 0/153 | 1/126 | 0/104 | 0/74 | 1/66 | 0/239 | 0/51 | 0/55 |
| TonsillitisInfections and infestations | 1/185 | 0/152 | 0/144 | 0/170 | 0/153 | 0/126 | 0/104 | 0/74 | 1/66 | 0/239 | 0/51 | 0/55 |
| StomatitisGastrointestinal disorders | 0/185 | 0/152 | 0/144 | 0/170 | 0/153 | 0/126 | 0/104 | 1/74 | 0/66 | 0/239 | 0/51 | 0/55 |
| UrticariaSkin and subcutaneous tissue disorders | 0/185 | 0/152 | 0/144 | 0/170 | 0/153 | 0/126 | 0/104 | 1/74 | 0/66 | 0/239 | 0/51 | 0/55 |
| Accidental exposure to productInjury, poisoning and procedural complications | 0/185 | 0/152 | 0/144 | 0/170 | 0/153 | 0/126 | 0/104 | 1/74 | 0/66 | 0/239 | 0/51 | 0/55 |
| PneumoniaInfections and infestations | 2/185 | 0/152 | 1/144 | 0/170 | 0/153 | 0/126 | 1/104 | 0/74 | 0/66 | 0/239 | 0/51 | 0/55 |
| Event | B+R246_12 | B+R246_18 | B+R246_24 | B246_12 | B246_18 | B246_24 | B+R234_12 | B+R234_18 | B+R234_24 | B12 14 | B18 20 | B24 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Injection site painGeneral disorders | 107/185 | 114/152 | 118/144 | 104/170 | 104/153 | 105/126 | 70/104 | 56/74 | 51/66 | 187/239 | 41/51 | 51/55 |
| Injection site erythemaGeneral disorders | 127/185 | 100/152 | 109/144 | 117/170 | 94/153 | 94/126 | 76/104 | 52/74 | 49/66 | 179/239 | 38/51 | 41/55 |
| IrritabilityPsychiatric disorders | 110/185 | 100/152 | 92/144 | 104/170 | 91/153 | 83/126 | 72/104 | 53/74 | 44/66 | 177/239 | 32/51 | 35/55 |
| Injection site indurationGeneral disorders | 101/185 | 74/152 | 76/144 | 93/170 | 62/153 | 73/126 | 52/104 | 41/74 | 35/66 | 148/239 | 27/51 | 33/55 |
| Eating disorderPsychiatric disorders | 64/185 | 70/152 | 68/144 | 66/170 | 59/153 | 51/126 | 41/104 | 29/74 | 28/66 | 126/239 | 21/51 | 34/55 |
| PyrexiaGeneral disorders | 78/185 | 57/152 | 50/144 | 60/170 | 59/153 | 32/126 | 53/104 | 28/74 | 27/66 | 133/239 | 24/51 | 22/55 |
| SomnolenceNervous system disorders | 72/185 | 61/152 | 72/144 | 63/170 | 56/153 | 52/126 | 50/104 | 33/74 | 27/66 | 129/239 | 25/51 | 28/55 |
| Injection site swellingGeneral disorders | 73/185 | 53/152 | 63/144 | 57/170 | 52/153 | 50/126 | 32/104 | 36/74 | 25/66 | 107/239 | 21/51 | 24/55 |
| CryingGeneral disorders | 56/185 | 43/152 | 46/144 | 52/170 | 51/153 | 40/126 | 41/104 | 18/74 | 22/66 | 105/239 | 17/51 | 25/55 |
| DiarrhoeaGastrointestinal disorders | 39/185 | 26/152 | 32/144 | 40/170 | 27/153 | 27/126 | 21/104 | 18/74 | 13/66 | 72/239 | 16/51 | 21/55 |
| Age, Categorical(Participants) | B+R246_12 | B+R246_18 | B+R246_24 | B246_12 | B246_18 | B246_24 | B+R234_12 | B+R234_18 | B+R234_24 | B12 14 | B18 20 | B24 26 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 188 | 157 | 152 | 174 | 164 | 143 | 106 | 78 | 73 | 246 | 51 | 56 | 1588 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(months) | B+R246_12 | B+R246_18 | B+R246_24 | B246_12 | B246_18 | B246_24 | B+R234_12 | B+R234_18 | B+R234_24 | B12 14 | B18 20 | B24 26 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 12.6 ± 1.2 | 18.1 ± 0.6 | 24 ± 0.4 | 12.7 ± 0.9 | 18.1 ± 0.5 | 24 ± 0.3 | 12.8 ± 1.4 | 18 ± 0.4 | 24 ± 0.5 | 12.6 ± 1.3 | 18 ± 0.2 | 24 ± 0.2 | 17.1 ± 4.7 |
| Sex: Female, Male(Participants) | B+R246_12 | B+R246_18 | B+R246_24 | B246_12 | B246_18 | B246_24 | B+R234_12 | B+R234_18 | B+R234_24 | B12 14 | B18 20 | B24 26 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 78 | 73 | 77 | 81 | 80 | 75 | 62 | 41 | 34 | 115 | 23 | 23 | 762 |
| Male | 110 | 84 | 75 | 93 | 84 | 68 | 44 | 37 | 39 | 131 | 28 | 33 | 826 |
The record gives a start of Jul 2009, a primary completion of Aug 2011 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 4 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 4CMenB vaccine